FDA Adverse Event Injury Summary report: N

OCUCOAT VISCOELASTIC

MDR report key: 18239957 · Received November 30, 2023

Report

Report Number
0001313525-2023-70130
Event Type
Injury
Date Received
November 30, 2023
Date of Event
October 19, 2023
Report Date
November 3, 2023
Manufacturer
BAUSCH + LOMB
Product Code
LZP
UDI-DI
00757770484799
PMA / PMN Number
P860047
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
TX, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

INVESTIGATION OF THIS EVENT IS IN PROGRESS. A FOLLOW-UP REPORT WILL BE SUBMITTED UPON COMPLETION OF INVESTIGATION.

Additional Manufacturer Narrative · 0

ALTHOUGH REQUESTED, THE DEVICE WAS NOT RETURNED FOR EVALUATION AND ADDITIONAL INFORMATION REGARDING THE EVENT WAS NOT PROVIDED. INVESTIGATION OF THIS EVENT IS IN PROGRESS. A FOLLOW-UP REPORT WILL BE SUBMITTED UPON COMPLETION OF INVESTIGATION.

Additional Manufacturer Narrative · 0

THE DEVICE INVOLVED IN THIS EVENT WAS NOT RETURNED FOR EVALUATION. TWO UNUSED UNITS FROM THE SAME LOT WERE RETURNED AND EVALUATED. EVALUATION OF THE RETURNED PRODUCT CONFIRMED THAT ALL PACKAGING SEALS WERE INTACT FOR EACH COMPONENT (CANNULA NEEDLE AND RETENTION CLIP) AND SYRINGE. NO SEALS WERE BROKEN AND THERE WERE NO VISIBLE INTEGRITY OR APPEARANCE ISSUES WITH ANY OF THE COMPONENTS OR SYRINGES. A REVIEW OF THE DEVICE HISTORY RECORD (DHR) DID NOT IDENTIFY ANY ANOMALIES OR NONCONFORMITIES THAT COULD BE RELATED TO THIS EVENT. THE LOT HISTORY, RISK ANALYSIS AND DIRECTIONS FOR USE REVIEW WERE CONSIDERED ACCEPTABLE, WITH THE PRODUCT PERFORMING WITHIN ANTICIPATED RATES. BASED ON THE AVAILABLE INFORMATION, THE ROOT CAUSE COULD NOT BE CONCLUSIVELY DETERMINED.

Description of Event or Problem · 0

ADDITIONAL INFORMATION WAS RECEIVED, INDICATING ORIGINAL PROCEDURE WAS NOT COMPLICATED IN ANY WAY. PROCEDURE WAS APPROXIMATELY 15-30 MINUTES. CLEAR CORNEAL INCISION UTILIZED. INCISION WAS NOT SUTURED AT THE TIME OF ORIGINAL SURGERY. CLEANING AND STERILIZATION METHODS USED PRIOR TO SURGERY: THE INSTRUMENTS WERE DECONTAMINATED AND WASHED USING MULTI-ENZYMATIC CLEANER AND DISTILLED WATER, STERILIZED USING A STEAM AUTOCLAVE. THERE WAS NO EVIDENCE OR SUSPICION OF A WOUND LEAK POSTOPERATIVELY. ANTIBIOTIC/ANTISEPTIC/STEROID MEDICATIONS USED PREOPERATIVELY: PROLENSA 1QTT BID OU 3 DAYS BEFORE SURGERY, BESIVANCE 1QTT BID OU 3 DAYS BEFORE SURGERY, LOTEMAX 1QTT 4X OU 3 DAYS BEFORE SURGERY. ANTIBIOTIC, STEROID, NSAID PRESCRIBED POSTOPERATIVELY: MOXIFLOXACIN 0.5% 1 GTT OU TID, KETOROLAC 0.5% 1 GTT OU TID, DUREZOL 0.05% 1 GTT OU QH. PATIENT UNCOOPERATIVE WITH TOPICAL REGIMEN DUE TO PAIN. ON POD1, PATIENT HAD SUB-TENON KENALOG INJECTION PERFORMED OU. ON POD2, PATIENT HAD PPV +INTRAVENOUS INJECTION OF ANTIBIOTICS AND ANTERIOR VIT BIOPSY OU. IN THE SURGEON''S OPINION, THE MOST LIKELY CAUSE OF EVENT IS POSTOPERATIVE INFECTION. RESULTS OF CULTURE & SENSITIVITY ARE PSEUDOMONAS AERUGINOSA SENSITIVITY. PATIENT OUTCOME IS POOR DUE TO NATURE OF SEVERE INFECTION, CAUSED BY P.AERUGINOSA ENDOPHTHALMITIS.

Description of Event or Problem · 0

IT WAS REPORTED THAT DURING THE ONE-DAY POST-OPERATIVE VISIT AFTER IMPLANTABLE COLLAMER LENS IMPLANTATION INTO BOTH EYES, THE SURGEON NOTED THE PATIENT PRESENTED WITH SEVERE CORNEAL EDEMA, INCREASED INTRAOCULAR PRESSURE AND SYMPTOMS OF POSSIBLE TASS. THE PATIENT WAS PRESCRIBED MEDICATION TO LOWER IOP AND REFERRED TO A RETINA SPECIALIST FOR FURTHER EVALUATION OF POSSIBLE CONDITIONS. DURING THE PATIENT'S SURGERY TWO UNITS WERE USED INDIVIDUALLY, ONE UNIT WAS USED FOR RIGHT EYE AND ONE UNIT WAS USED ON LEFT EYE. ADDITIONAL INFORMATION WAS REQUESTED, BUT NOT RECEIVED.

Description of Event or Problem · 0

THIS IS THE REPORT FOR THE RIGHT EYE (OD). LEFT EYE (OS) REFERENCE:0001313525-2024-70065.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1939888 OCUCOAT VISCOELASTIC AID, SURGICAL, VISCOELASTIC LZP BAUSCH + LOMB CC065S 029923 00757770484799

Patients

Seq Age Sex Outcome Treatment
1 29 YR Female Required Intervention ICL LENS| LIOLI-24 INJECTOR, BETADINE-IODINE, MOXIFLOXACIN PF